Arcellx: Funding, Investors & Team (Sep 2026)
Arcellx is a clinical-stage biotechnology organization reconsidering cell treatment by designing inventive immunotherapies for patients with malignant growth and other serious infections. Arcellx accepts that cell treatments are one of the forward mainstays of medication and Arcellx's central goal is to propel mankind by creating cell treatments that are more secure, more successful, and all the more extensively available. Arcellx's lead item competitor, CART-ddBCMA, is being created for the treatment of backslid or hard-headed numerous myeloma (r/r MM) in a continuous Phase 1 review. Truck ddBCMA has been conceded Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy assignments by the U.S. Food and Drug Administration. Arcellx is likewise propelling its dosable and controllable CAR-T treatment, ARC-SparX, into the center through two projects: ACLX-001 in r/r MM and ACLX-002 in backslid or unmanageable intense myeloid leukemia.
Arcellx has raised $222M across 3 funding rounds on record, the most recent an undisclosed round of $100M announced in Dec 2022.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Arcellx Company Profile and Key Stats
Latest funding round on record: Dec 2022.
Arcellx Funding Rounds
Arcellx raised $10.0M in a Post-IPO Equity announced in Mar 2022.
3 months later, a Post-IPO Equity of $112M was announced in Jun 2022.
6 months later, an undisclosed round of $100M was announced in Dec 2022.
Arcellx Founders and Leadership Team
Contact details for the Arcellx team: 2 of 2 have an email address on file.
Start 14-day free trial →Arcellx Funding Compared to Other Biotechnology Startups
Arcellx's latest round of $100M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Arcellx in Biotechnology and Gaithersburg
Companies Similar to Arcellx
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Arcellx Funding FAQs
What does Arcellx do?
Arcellx is a clinical-stage biotechnology organization reconsidering cell treatment by designing inventive immunotherapies for patients with malignant growth and other serious infections. Arcellx accepts that cell treatments are one of the forward mainstays of medication and Arcellx's central goal is to propel mankind by creating cell treatments that are more secure, more successful, and all the more extensively available. Arcellx's lead item competitor, CART-ddBCMA, is being created for the treatment of backslid or hard-headed numerous myeloma (r/r MM) in a continuous Phase 1 review. Truck ddBCMA has been conceded Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy assignments by the U.S. Food and Drug Administration. Arcellx is likewise propelling its dosable and controllable CAR-T treatment, ARC-SparX, into the center through two projects: ACLX-001 in r/r MM and ACLX-002 in backslid or unmanageable intense myeloid leukemia.
How much funding has Arcellx raised?
Arcellx has raised $222M across 3 rounds on record. The most recent is an undisclosed round of $100M announced in Dec 2022.
When did Arcellx last raise funding?
Arcellx's most recent funding round on record is an undisclosed round of $100M, announced in Dec 2022.
Who is the CEO of Arcellx?
David Hilbert is listed as CEO at Arcellx.
Where is Arcellx headquartered?
Arcellx is based in Gaithersburg, Maryland, United States.
How many employees does Arcellx have?
Arcellx is in the 51-100 employee band.
How does Arcellx's funding compare to other Biotechnology startups?
Arcellx's latest round of $100M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Arcellx Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Arcellx is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.